Here’s what you should know:
1. SYN-010 is a proprietary, modified-release lovastatin lactone formulation used for constipation treatments.
2. The company will be able to protect SYN-010 until at least 2034, allowing for a period of extended commercialization.
3. Fifty-five U.S. and foreign patents protect SYN-010. There are another 25 patents pending.
Synthetic Biologics CEO Jeffrey Riley said in a release, “Once issued, this patent will extend the protection around the use of SYN-010 to treat IBS-C by an additional eleven years and significantly strengthens the opportunity to build long-term value for our shareholders.”
More articles on gastroenterology:
Analysts predict the uncertain future of Ironwood Pharmaceuticals — 4 insights
GI center to know: Gastroenterology Associates
GI leader to know: Dr. Steven Condron of Avera Medical Group
